Solventum Corp（SOLV）の決算・業績分析
Solventum Corpの2025年有価証券報告書をAI分析。売上高$8.3B(+0.9%)。営業利益$2.2B。Health Care。
目次
Solventum Corpの2025年度 業績サマリー
Solventum Corp（証券コード: SOLV）の2025年度決算・業績分析。売上高は$8.3B（前年比+0.9%）。営業利益は$2.2B（前年比+110.5%）。純利益は$1.6B（前年比+224.8%）。有価証券報告書を基に、業績変化の要因・リスク・見通し・セグメント構成を AI が分析しました。
Solventum Corpの2024年度 注目ポイント
※ 直近の2025年度XBRLデータは取込済みですが、AI分析は2024年度の10-Kを対象としています。
- Solventum Corp achieved $8.1B in FY2024 revenue (XBRL), with a 57.8% gross margin (XBRL) and 16.5% net margin (XBRL).
- The company maintains a strong financial position with an 86.5% equity ratio (XBRL) and no long-term debt (XBRL), resulting in a net debt of -$194M (-0.1x EBITDA) (XBRL).
- ROE of 11.1% (XBRL) and ROA of 9.6% (XBRL) reflect efficient capital utilization despite a 0.8% CAGR in revenue over five years (XBRL).
Solventum Corpの売上高変化の要因
- •FY2024 revenue of $8.1B (XBRL) was driven by MedSurg (56.2% of sales) and Health Information Systems (15.8%) (10-K). Revenue growth over five years was modest at 0.8% CAGR (XBRL), with operating income flat at -0.1% CAGR (XBRL). The historical time series shows revenue increased slightly to $8.2B in FY2025 (XBRL), but operating income remained stable at $1.7B (XBRL).
Solventum Corpの営業利益変化の要因
- •Profitability metrics include a 27.9% EBITDA margin (XBRL), 20.8% operating margin (XBRL), and 16.5% net margin (XBRL). Gross profit of $4.7B (XBRL) reflects strong cost control, though operating income growth has stagnated (-0.1% CAGR) (XBRL). YoY changes in profitability metrics are not quantified in the data (N/A).
Solventum Corpの事業リスクと対応
Post-Spin-Off financial performance may not reflect Solventum’s standalone capabilities (10-K).
Failure to realize Spin-Off benefits could harm business operations (10-K).
Inadequate financial systems for standalone reporting may lead to compliance risks (10-K).
Debt obligations from the Spin-Off could strain liquidity (10-K).
Reliance on 3M for commercial relationships may limit operational independence (10-K).
Regulatory risks include compliance with healthcare laws, PFAS liabilities, and international trade regulations (10-K).
Solventum Corpの事業内容
Solventum Corp operates in the healthcare sector, leveraging material science, data science, and digital capabilities to develop, manufacture, and commercialize healthcare solutions (10-K). Its business model generates revenue through four core segments: MedSurg (56.2% of sales), Dental Solutions (15.7%), Health Information Systems (15.8%), and Purification and Filtration (11.6%) (10-K). Key products include wound care solutions, surgical supplies, dental aligners, healthcare software, and biopharmaceutical filtration technologies. Competitive advantages include strong customer relationships, differentiated technology, and a diversified customer base with no significant concentration (10-K). The R&D team comprises ~2,000 employees (10-K), though total workforce size is unspecified.
Solventum CorpのAI業績分析レポート（2024年度）
Solventum Corp (SOLV) FY2024 Annual Report Analysis
Highlights
Business Overview
Solventum Corp operates in healthcare, leveraging material science and digital capabilities to develop products and services across four segments: MedSurg (56.2% of sales), Dental Solutions (15.7%), Health Information Systems (15.8%), and Purification and Filtration (11.6%) (10-K). The company’s competitive advantages include strong customer relationships and a diversified customer base (10-K). R&D teams consist of ~2,000 employees (10-K), though total workforce size is unspecified.
Revenue Analysis
FY2024 revenue of $8.1B (XBRL) was driven by MedSurg and Health Information Systems. Revenue grew 0.8% CAGR over five years (XBRL), but operating income stagnated (-0.1% CAGR) (XBRL). Historical data shows revenue increased to $8.2B in FY2025 (XBRL), with operating income remaining stable at $1.7B (XBRL).
Profitability Analysis
Profitability metrics include a 27.9% EBITDA margin (XBRL), 20.8% operating margin (XBRL), and 16.5% net margin (XBRL). Gross profit of $4.7B (XBRL) reflects strong cost control, though operating income growth has stagnated (-0.1% CAGR) (XBRL). YoY changes in profitability metrics are not quantified in the data (N/A).
Balance Sheet Analysis
The balance sheet shows a robust equity ratio of 86.5% (XBRL) and no long-term debt (XBRL), resulting in a net debt of -$194M (-0.1x EBITDA) (XBRL). Total assets grew to $13.9B (XBRL), while total equity declined slightly to $12.1B (XBRL) in FY2024. Current ratio of 1.46x (XBRL) indicates strong short-term liquidity.
Cash Flow Analysis
Operating cash flow was $1.7B (XBRL), with $1.4B in free cash flow (FCF) after $251M in CapEx (XBRL). Investing cash flow was -$253M (XBRL), primarily from capital expenditures. Financing cash flow was -$1.5B (XBRL), reflecting debt obligations from the Spin-Off (10-K). R&D expense totaled $767M (XBRL).
Working Capital Analysis
Cash conversion cycle (CCC) was 76 days (XBRL), with 59 days of receivables, 38 days of inventory, and 21 days of payables (XBRL).
Risks
Outlook
No management guidance or forward-looking trends are explicitly mentioned in the 10-K or XBRL data (N/A).
Health Careの企業一覧
Solventum Corpと同じ「Health Care」セクターの企業